{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T14:47:20Z","timestamp":1790693240064,"version":"4.1.0"},"reference-count":199,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2019,5,22]],"date-time":"2019-05-22T00:00:00Z","timestamp":1558483200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>There is growing evidence that glucose metabolism in the liver is in part under the control of the endocannabinoid system (ECS) which is also supported by its presence in this organ. The ECS consists of its cannabinoid receptors (CBRs) and enzymes that are responsible for endocannabinoid production and metabolism. ECS is known to be differentially influenced by the hepatic glucose metabolism and insulin resistance, e.g., cannabinoid receptor type 1(CB1) antagonist can improve the glucose tolerance and insulin resistance. Interestingly, our own study shows that expression patterns of CBRs are influenced by the light\/dark cycle, which is of significant physiological and clinical interest. The ECS system is highly upregulated during chronic liver disease and a growing number of studies suggest a mechanistic and therapeutic impact of ECS on the development of liver fibrosis, especially putting its receptors into focus. An opposing effect of the CBRs was exerted via the CB1 or CB2 receptor stimulation. An activation of CB1 promoted fibrogenesis, while CB2 activation improved antifibrogenic responses. However, underlying mechanisms are not yet clear. In the context of liver diseases, the ECS is considered as a possible mediator, which seems to be involved in the synthesis of fibrotic tissue, increase of intrahepatic vascular resistance and subsequently development of portal hypertension. Portal hypertension is the main event that leads to complications of the disease. The main complication is the development of variceal bleeding and ascites, which have prognostic relevance for the patients. The present review summarizes the current understanding and impact of the ECS on glucose metabolism in the liver, in association with the development of liver cirrhosis and hemodynamics in cirrhosis and its complication, to give perspectives for development of new therapeutic strategies.<\/jats:p>","DOI":"10.3390\/ijms20102516","type":"journal-article","created":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T03:22:03Z","timestamp":1558581723000},"page":"2516","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":78,"title":["Endocannabinoid System in Hepatic Glucose Metabolism, Fatty Liver Disease, and Cirrhosis"],"prefix":"10.3390","volume":"20","author":[{"given":"Ivonne","family":"Bazwinsky-Wutschke","sequence":"first","affiliation":[{"name":"Department of Anatomy and Cell Biology, Martin Luther University Halle-Wittenberg, Grosse Steinstrasse 52, D-06108 Halle (Saale), Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Zipprich","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Hepatology, Clinic of Internal Medicine I, Martin Luther University Halle-Wittenberg, Ernst-Grube-Strasse 40, D-06120 Halle (Saale), Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7615-8854","authenticated-orcid":false,"given":"Faramarz","family":"Dehghani","sequence":"additional","affiliation":[{"name":"Department of Anatomy and Cell Biology, Martin Luther University Halle-Wittenberg, Grosse Steinstrasse 52, D-06108 Halle (Saale), Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2019,5,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"R309","DOI":"10.1530\/EJE-16-1044","article-title":"MECHANISMS IN ENDOCRINOLOGY: Endocannabinoids and metabolism: Past, present and future","volume":"176","author":"Simon","year":"2017","journal-title":"Eur. J. Endocrinol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/sj.bjp.0705666","article-title":"The endocannabinoid system: A general view and latest additions","volume":"141","author":"Cascio","year":"2004","journal-title":"Br. J. Pharmacol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.neuropharm.2004.07.030","article-title":"Cannabinoid physiology and pharmacology: 30 years of progress","volume":"47","author":"Howlett","year":"2004","journal-title":"Neuropharmacology"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.drudis.2008.09.001","article-title":"CB(1) receptor antagonism: Biological basis for metabolic effects","volume":"13","year":"2008","journal-title":"Drug Discov. Today"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1124\/pr.110.003004","article-title":"International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: Beyond CB\u2081 and CB\u2082","volume":"62","author":"Pertwee","year":"2010","journal-title":"Pharmacol. Rev."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1038\/nrn1247","article-title":"The molecular logic of endocannabinoid signalling","volume":"4","author":"Piomelli","year":"2003","journal-title":"Nat. Rev. Neurosci."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.lfs.2005.05.055","article-title":"Cannabinoid signalling","volume":"78","author":"Demuth","year":"2006","journal-title":"Life Sci."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1038\/sj.bjp.0707423","article-title":"Cannabinoids go nuclear: Evidence for activation of peroxisome proliferator-activated receptors","volume":"152","year":"2007","journal-title":"Br. J. Pharmacol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.ejphar.2005.05.032","article-title":"Anandamide induced PPARgamma transcriptional activation and 3T3-L1 preadipocyte differentiation","volume":"517","author":"Bouaboula","year":"2005","journal-title":"Eur. J. Pharmacol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1194\/jlr.M700354-JLR200","article-title":"Identification of biosynthetic precursors for the endocannabinoid anandamide in the rat brain","volume":"49","author":"Astarita","year":"2008","journal-title":"J. Lipid Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1152\/physrev.00019.2008","article-title":"Endocannabinoid-mediated control of synaptic transmission","volume":"89","author":"Kano","year":"2009","journal-title":"Physiol. Rev."},{"key":"ref_12","first-page":"549","article-title":"Endocannabinoid regulation of \u03b2-cell functions: Implications for glycaemic control and diabetes","volume":"18","author":"Jourdan","year":"2016","journal-title":"DiabetesObes. Metab."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/346561a0","article-title":"Structure of a cannabinoid receptor and functional expression of the cloned cDNA","volume":"346","author":"Matsuda","year":"1990","journal-title":"Nature"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1073\/pnas.87.5.1932","article-title":"Cannabinoid receptor localization in brain","volume":"87","author":"Herkenham","year":"1990","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/365061a0","article-title":"Molecular characterization of a peripheral receptor for cannabinoids","volume":"365","author":"Munro","year":"1993","journal-title":"Nature"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0014-2999(00)00211-9","article-title":"Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB(2) receptor","volume":"396","author":"Buckley","year":"2000","journal-title":"Eur. J. Pharmacol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1089\/can.2017.0036","article-title":"An Update on Non-CB1, Non-CB2 Cannabinoid Related G-Protein-Coupled Receptors","volume":"2","author":"Morales","year":"2017","journal-title":"Cannabis Cannabinoid Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1523\/JNEUROSCI.11-02-00563.1991","article-title":"Characterization and localization of cannabinoid receptors in rat brain: A quantitative in vitro autoradiographic study","volume":"11","author":"Herkenham","year":"1991","journal-title":"J. Neurosci."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1126\/science.1470919","article-title":"Isolation and structure of a brain constituent that binds to the cannabinoid receptor","volume":"258","author":"Devane","year":"1992","journal-title":"Science"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"422","DOI":"10.2174\/187152709789824615","article-title":"Signal transduction via cannabinoid receptors","volume":"8","author":"Dalton","year":"2009","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1126\/science.1115740","article-title":"Identification and functional characterization of brainstem cannabinoid CB2 receptors","volume":"310","year":"2005","journal-title":"Science"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3984","DOI":"10.1073\/pnas.93.9.3984","article-title":"The ALIAmide palmitoylethanolamide and cannabinoids, but not anandamide, are protective in a delayed postglutamate paradigm of excitotoxic death in cerebellar granule neurons","volume":"93","author":"Skaper","year":"1996","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1002\/syn.20050","article-title":"Cannabinoid CB2 receptors are expressed by perivascular microglial cells in the human brain: An immunohistochemical study","volume":"53","author":"Benito","year":"2004","journal-title":"Synapse"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1007\/s00109-005-0698-5","article-title":"The endocannabinoid system in the physiology and pathophysiology of the gastrointestinal tract","volume":"83","author":"Massa","year":"2005","journal-title":"J. Mol. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1172\/JCI200523057","article-title":"Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity","volume":"115","author":"DePetrillo","year":"2005","journal-title":"J. Clin. Investig."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1007\/BF03348205","article-title":"Antagonizing the cannabinoid receptor type 1: A dual way to fight obesity","volume":"26","author":"Cota","year":"2003","journal-title":"J. Endocrinol. Investig."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.bbrc.2008.05.077","article-title":"The cannabinoid CB1 receptor is expressed in pancreatic delta-cells","volume":"372","author":"Tharp","year":"2008","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/dom.12144","article-title":"The cannabinoid receptor 1 and its role in influencing peripheral metabolism","volume":"16","author":"Simcocks","year":"2014","journal-title":"Diabetes Obes. Metab."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0167-4781(02)00341-X","article-title":"Cloning and molecular characterization of the rat CB2 cannabinoid receptor","volume":"1576","author":"Brown","year":"2002","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1053\/j.gastro.2004.12.050","article-title":"Antifibrogenic role of the cannabinoid receptor CB2 in the liver","volume":"128","author":"Julien","year":"2005","journal-title":"Gastroenterology"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/j.1478-3231.2006.01401.x","article-title":"Endocannabinoid receptor CB2 in nonalcoholic fatty liver disease","volume":"27","author":"Uribe","year":"2007","journal-title":"Liver Int."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nm1421","article-title":"CB1 cannabinoid receptor antagonism: A new strategy for the treatment of liver fibrosis","volume":"12","author":"Julien","year":"2006","journal-title":"Nat. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1016\/S0306-4522(97)00348-5","article-title":"Expression of the CB1 and CB2 receptor messenger RNAs during embryonic development in the rat","volume":"82","author":"Buckley","year":"1998","journal-title":"Neuroscience"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"502542","DOI":"10.1155\/2014\/502542","article-title":"Endocannabinoid receptors gene expression in morbidly obese women with nonalcoholic fatty liver disease","volume":"2014","author":"Auguet","year":"2014","journal-title":"BioMed Res. Int."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.tips.2015.02.008","article-title":"Endocannabinoid signaling at the periphery: 50 years after THC","volume":"36","author":"Maccarrone","year":"2015","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1111\/j.1476-5381.2011.01397.x","article-title":"The endocannabinoid system as a key mediator during liver diseases: New insights and therapeutic openings","volume":"163","author":"Mallat","year":"2011","journal-title":"Br. J. Pharmacol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.jhep.2013.03.032","article-title":"Cannabinoid signaling and liver therapeutics","volume":"59","author":"Mallat","year":"2013","journal-title":"J. Hepatol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"144","DOI":"10.4103\/1319-3767.114505","article-title":"The role of endocannabinoids system in fatty liver disease and therapeutic potentials","volume":"19","author":"Alswat","year":"2013","journal-title":"Saudi J. Gastroenterol."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Deveaux, V., Cadoudal, T., Ichigotani, Y., Teixeira-Clerc, F., Louvet, A., Manin, S., Nhieu, J.T.-V., Belot, M.P., Zimmer, A., and Even, P. (2009). Cannabinoid CB2 receptor potentiates obesity-associated inflammation, insulin resistance and hepatic steatosis. PLoS ONE, 4.","DOI":"10.1371\/journal.pone.0005844"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"33302","DOI":"10.1038\/srep33302","article-title":"Human CB1 Receptor Isoforms, present in Hepatocytes and \u03b2-cells, are Involved in Regulating Metabolism","volume":"6","author":"Doyle","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Abood, M., Sorensen, R., and Stella, N. (2013). Overview of Nonclassical Cannabinoid Receptors. The Receptors, Springer.","DOI":"10.1007\/978-1-4614-4669-9"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0306-4522(01)00335-9","article-title":"The proximal and distal C-terminal tail domains of the CB1 cannabinoid receptor mediate G protein coupling","volume":"107","author":"Nie","year":"2001","journal-title":"Neuroscience"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"8758","DOI":"10.1523\/JNEUROSCI.21-22-08758.2001","article-title":"Structural domains of the CB1 cannabinoid receptor that contribute to constitutive activity and G-protein sequestration","volume":"21","author":"Nie","year":"2001","journal-title":"J. Neurosci."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1471-4159.2011.07186.x","article-title":"The cannabinoid type-1 receptor carboxyl-terminus, more than just a tail","volume":"117","author":"Stadel","year":"2011","journal-title":"J. Neurochem."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Bazwinsky-Wutschke, I., Zipprich, A., and Dehghani, F. (2017). Daytime-Dependent Changes of Cannabinoid Receptor Type 1 and Type 2 Expression in Rat Liver. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18091844"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"21453","DOI":"10.1073\/pnas.0909591106","article-title":"Time of feeding and the intrinsic circadian clock drive rhythms in hepatic gene expression","volume":"106","author":"Vollmers","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"27971","DOI":"10.1074\/jbc.M111.224352","article-title":"Cannabinoid receptor type 1 (CB1R) signaling regulates hepatic gluconeogenesis via induction of endoplasmic reticulum-bound transcription factor cAMP-responsive element-binding protein H (CREBH) in primary hepatocytes","volume":"286","author":"Chanda","year":"2011","journal-title":"J. Biol. Chem."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"3369","DOI":"10.2337\/db16-0298","article-title":"CREBH Couples Circadian Clock With Hepatic Lipid Metabolism","volume":"65","author":"Zheng","year":"2016","journal-title":"Diabetes"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"38041","DOI":"10.1074\/jbc.M112.377978","article-title":"Activation of cannabinoid receptor type 1 (Cb1r) disrupts hepatic insulin receptor signaling via cyclic AMP-response element-binding protein H (Crebh)-mediated induction of Lipin1 gene","volume":"287","author":"Chanda","year":"2012","journal-title":"J. Biol. Chem."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"15172","DOI":"10.1073\/pnas.0806717105","article-title":"Physiological significance of a peripheral tissue circadian clock","volume":"105","author":"Lamia","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/0005-2760(91)90168-H","article-title":"Diurnal variations of lipogenic enzyme mRNA quantities in rat liver","volume":"1086","author":"Fukuda","year":"1991","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_52","first-page":"239","article-title":"Lipogenic activities in rat liver are subjected to circadian rhythms","volume":"50","author":"Zardoya","year":"1994","journal-title":"Rev. Esp. De Fisiol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1016\/j.amjmed.2007.06.007","article-title":"Understanding metabolic homeostasis and imbalance: What is the role of the endocannabinoid system?","volume":"120","author":"Kunos","year":"2007","journal-title":"Am. J. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"18832","DOI":"10.1073\/pnas.1309469110","article-title":"Monounsaturated fatty acids generated via stearoyl CoA desaturase-1 are endogenous inhibitors of fatty acid amide hydrolase","volume":"110","author":"Liu","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"RC17","DOI":"10.1007\/BF03347440","article-title":"Insulin differentially modulates the peripheral endocannabinoid system in human subcutaneous abdominal adipose tissue from lean and obese individuals","volume":"30","author":"Murdolo","year":"2007","journal-title":"J. Endocrinol. Investig."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"R345","DOI":"10.1152\/ajpregu.00545.2002","article-title":"Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice","volume":"284","author":"Arnone","year":"2003","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/hep.26606","article-title":"Hepatic cannabinoid-1 receptors mediate diet-induced insulin resistance by increasing de novo synthesis of long-chain ceramides","volume":"59","author":"Cinar","year":"2014","journal-title":"Hepatology"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1002\/hep.24733","article-title":"Antagonism of peripheral hepatic cannabinoid receptor-1 improves liver lipid metabolism in mice: Evidence from cultured explants","volume":"55","author":"Jourdan","year":"2012","journal-title":"Hepatology"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.2337\/db08-0161","article-title":"Peripheral, but not central, CB1 antagonism provides food intake-independent metabolic benefits in diet-induced obese rats","volume":"57","author":"Nogueiras","year":"2008","journal-title":"Diabetes"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1111\/j.1478-3231.2010.02298.x","article-title":"Cannabinoid receptor 1 and 2 agonists increase lipid accumulation in hepatocytes","volume":"30","author":"Spahr","year":"2010","journal-title":"Liver Int."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Chen, J., Montagner, A., Tan, N.S., and Wahli, W. (2018). Insights into the Role of PPAR\u03b2\/\u03b4 in NAFLD. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19071893"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1124\/mol.111.072769","article-title":"Rimonabant, a cannabinoid receptor type 1 inverse agonist, inhibits hepatocyte lipogenesis by activating liver kinase B1 and AMP-activated protein kinase axis downstream of G\u03b1 i\/o inhibition","volume":"80","author":"Wu","year":"2011","journal-title":"Mol. Pharmacol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2953","DOI":"10.1172\/JCI42551","article-title":"Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity","volume":"120","author":"Tam","year":"2010","journal-title":"J. Clin. Investig."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.cmet.2012.07.002","article-title":"Peripheral cannabinoid-1 receptor inverse agonism reduces obesity by reversing leptin resistance","volume":"16","author":"Tam","year":"2012","journal-title":"Cell Metab."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1002\/hep.21641","article-title":"Rimonabant reduces obesity-associated hepatic steatosis and features of metabolic syndrome in obese Zucker fa\/fa rats","volume":"46","author":"Elachouri","year":"2007","journal-title":"Hepatology"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"926","DOI":"10.2337\/db09-1482","article-title":"CB1 antagonism exerts specific molecular effects on visceral and subcutaneous fat and reverses liver steatosis in diet-induced obese mice","volume":"59","author":"Jourdan","year":"2010","journal-title":"Diabetes"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1053\/j.gastro.2012.01.032","article-title":"Hepatic cannabinoid receptor-1 mediates diet-induced insulin resistance via inhibition of insulin signaling and clearance in mice","volume":"142","author":"Liu","year":"2012","journal-title":"Gastroenterology"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"14561","DOI":"10.1073\/pnas.0807232105","article-title":"Overactive endocannabinoid signaling impairs apolipoprotein E-mediated clearance of triglyceride-rich lipoproteins","volume":"105","author":"Ruby","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.1172\/JCI34827","article-title":"Hepatic CB1 receptor is required for development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in mice","volume":"118","author":"Liu","year":"2008","journal-title":"J. Clin. Investig."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/acel.12438","article-title":"CB1 receptor blockade counters age-induced insulin resistance and metabolic dysfunction","volume":"15","author":"Lipina","year":"2016","journal-title":"Aging Cell"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1007\/s00125-010-1894-6","article-title":"Deficiency of CB2 cannabinoid receptor in mice improves insulin sensitivity but increases food intake and obesity with age","volume":"53","author":"Agudo","year":"2010","journal-title":"Diabetologia"},{"key":"ref_72","first-page":"98","article-title":"Non-alcoholic steatohepatitis: Association with obesity and insulin resistance, and influence of weight loss","volume":"26","author":"Luyckx","year":"2000","journal-title":"Diabetes Metab."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1080\/07853890510037383","article-title":"Fat in the liver and insulin resistance","volume":"37","year":"2005","journal-title":"Ann. Med."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"4751","DOI":"10.1016\/j.bmcl.2013.06.066","article-title":"Peripherally restricted CB1 receptor blockers","volume":"23","author":"Chorvat","year":"2013","journal-title":"Bioorganic Med. Chem. Lett."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1111\/j.1478-3231.2007.01555.x","article-title":"Rimonabant as a novel therapeutic option for nonalcoholic steatohepatitis","volume":"27","author":"Banasch","year":"2007","journal-title":"Liver Int."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1097\/MCO.0b013e3282fcea11","article-title":"Inhibitors of cannabinoid receptors and glucose metabolism","volume":"11","author":"Scheen","year":"2008","journal-title":"Curr. Opin. Clin. Nutr. Metab. Care"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"44234","DOI":"10.1074\/jbc.M112.364109","article-title":"The cannabinoid receptor CB1 modulates the signaling properties of the lysophosphatidylinositol receptor GPR55","volume":"287","author":"Kargl","year":"2012","journal-title":"J. Biol. Chem."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1038\/sj.bjp.0707464","article-title":"GPR55: A new member of the cannabinoid receptor clan?","volume":"152","author":"Pertwee","year":"2007","journal-title":"Br. J. Pharmacol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1038\/sj.bjp.0707460","article-title":"The orphan receptor GPR55 is a novel cannabinoid receptor","volume":"152","author":"Ryberg","year":"2007","journal-title":"Br. J. Pharmacol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1073\/pnas.0711278105","article-title":"GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current","volume":"105","author":"Lauckner","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.2174\/092986710790980069","article-title":"GPR55: Current knowledge and future perspectives of a purported \u201cType-3\u201d cannabinoid receptor","volume":"17","author":"Moriconi","year":"2010","journal-title":"Curr. Med. Chem."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/j.1747-0285.2006.00370.x","article-title":"GPR55 as a new cannabinoid receptor: Still a long way to prove it","volume":"67","author":"Petitet","year":"2006","journal-title":"Chem. Biol. Drug Des."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.pharmthera.2010.02.004","article-title":"Pharmacological characterization of GPR55, a putative cannabinoid receptor","volume":"126","author":"Sharir","year":"2010","journal-title":"Pharmacol. Ther."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0169-328X(98)00277-0","article-title":"Identification and cloning of three novel human G protein-coupled receptor genes GPR52, PsiGPR53 and GPR55: GPR55 is extensively expressed in human brain","volume":"64","author":"Sawzdargo","year":"1999","journal-title":"Brain Res. Mol. Brain Res."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"281","DOI":"10.2337\/db11-0649","article-title":"The L-\u03b1-lysophosphatidylinositol\/GPR55 system and its potential role in human obesity","volume":"61","author":"Whyte","year":"2012","journal-title":"Diabetes"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/j.drudis.2013.12.005","article-title":"A potential role for GPR55 in the regulation of energy homeostasis","volume":"19","author":"Simcocks","year":"2014","journal-title":"Drug Discov. Today"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1093\/jb\/mvn136","article-title":"2-Arachidonoyl-sn-glycero-3-phosphoinositol: A possible natural ligand for GPR55","volume":"145","author":"Oka","year":"2009","journal-title":"J. Biochem."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.jpba.2016.04.011","article-title":"Development and validation of a specific and sensitive HPLC-ESI-MS method for quantification of lysophosphatidylinositols and evaluation of their levels in mice tissues","volume":"126","author":"Masquelier","year":"2016","journal-title":"J. Pharm. Biomed. Anal."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1096\/fj.201800171R","article-title":"GPR55 deficiency is associated with increased adiposity and impaired insulin signaling in peripheral metabolic tissues","volume":"33","author":"Lipina","year":"2018","journal-title":"FASEB J."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/j.1463-1326.2011.01515.x","article-title":"The atypical cannabinoid O-1602 stimulates food intake and adiposity in rats","volume":"14","author":"Pulido","year":"2012","journal-title":"Diabetes Obes. Metab."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1038\/cr.2011.60","article-title":"GPR55 regulates cannabinoid 2 receptor-mediated responses in human neutrophils","volume":"21","author":"Balenga","year":"2011","journal-title":"Cell Res."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3389\/fphar.2015.00069","article-title":"The therapeutic potential of orphan GPCRs, GPR35 and GPR55","volume":"6","author":"Shore","year":"2015","journal-title":"Front. Pharmacol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1038\/bjp.2008.337","article-title":"Endogenous and synthetic agonists of GPR119 differ in signalling pathways and their effects on insulin secretion in MIN6c4 insulinoma cells","volume":"155","author":"Ning","year":"2008","journal-title":"Br. J. Pharmacol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s00592-015-0826-9","article-title":"G protein-coupled receptors: Signalling and regulation by lipid agonists for improved glucose homoeostasis","volume":"53","author":"Moran","year":"2016","journal-title":"Acta Diabetol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1096\/fj.15-273771","article-title":"GPR119: A promising target for nonalcoholic fatty liver disease","volume":"30","author":"Yang","year":"2016","journal-title":"FASEB J."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/dom.13062","article-title":"Therapeutic application of GPR119 ligands in metabolic disorders","volume":"20","author":"Yang","year":"2018","journal-title":"Diabetes Obes. Metab."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ejphar.2017.02.043","article-title":"APD668, a G protein-coupled receptor 119 agonist improves fat tolerance and attenuates fatty liver in high-trans fat diet induced steatohepatitis model in C57BL\/6 mice","volume":"801","author":"Bahirat","year":"2017","journal-title":"Eur. J. Pharmacol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1016\/j.bbrc.2017.12.004","article-title":"Co-administration of APD668, a G protein-coupled receptor 119 agonist and linagliptin, a DPPIV inhibitor, prevents progression of steatohepatitis in mice fed on a high trans-fat diet","volume":"495","author":"Bahirat","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s00018-003-3216-3","article-title":"Peroxisome proliferator-activated receptor alpha target genes","volume":"61","author":"Mandard","year":"2004","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.2174\/092986710790980014","article-title":"From surface to nuclear receptors: The endocannabinoid family extends its assets","volume":"17","author":"Pistis","year":"2010","journal-title":"Curr. Med. Chem."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1111\/bph.13497","article-title":"An update on PPAR activation by cannabinoids","volume":"173","year":"2016","journal-title":"Br. J. Pharmacol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/35013000","article-title":"Roles of PPARs in health and disease","volume":"405","author":"Kersten","year":"2000","journal-title":"Nature"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.tem.2012.05.001","article-title":"PPARs at the crossroads of lipid signaling and inflammation","volume":"23","author":"Wahli","year":"2012","journal-title":"Trends Endocrinol. Metab."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"3370","DOI":"10.2174\/09298673113209990136","article-title":"Hepatic PPARs: Their role in liver physiology, fibrosis and treatment","volume":"20","author":"Zardi","year":"2013","journal-title":"Curr. Med. Chem."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S0140-6736(09)61040-0","article-title":"PPAR-alpha and PPAR-gamma agonists for type 2 diabetes","volume":"374","author":"Charbonnel","year":"2009","journal-title":"Lancet"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1172\/JCI27989","article-title":"Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasis","volume":"116","author":"Lefebvre","year":"2006","journal-title":"J. Clin. Investig."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.bbalip.2011.10.016","article-title":"Roles of PPARs in NAFLD: Potential therapeutic targets","volume":"1821","author":"Tailleux","year":"2012","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1093\/carcin\/21.4.823","article-title":"Peroxisome proliferator-activated receptor alpha is restricted to hepatic parenchymal cells, not Kupffer cells: Implications for the mechanism of action of peroxisome proliferators in hepatocarcinogenesis","volume":"21","author":"Peters","year":"2000","journal-title":"Carcinogenesis"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"25448","DOI":"10.1074\/jbc.M301189200","article-title":"Specific gene expression of ATP-binding cassette transporters and nuclear hormone receptors in rat liver parenchymal, endothelial, and Kupffer cells","volume":"278","author":"Hoekstra","year":"2003","journal-title":"J. Biol. Chem."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1136\/gutjnl-2015-310798","article-title":"Liver PPAR\u03b1 is crucial for whole-body fatty acid homeostasis and is protective against NAFLD","volume":"65","author":"Montagner","year":"2016","journal-title":"Gut"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.mce.2017.07.035","article-title":"Insights into the role of hepatocyte PPAR\u03b1 activity in response to fasting","volume":"471","author":"Polizzi","year":"2018","journal-title":"Mol. Cell. Endocrinol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/384039a0","article-title":"The PPARalpha-leukotriene B4 pathway to inflammation control","volume":"384","author":"Devchand","year":"1996","journal-title":"Nature"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"16154","DOI":"10.1074\/jbc.M400346200","article-title":"Global suppression of IL-6-induced acute phase response gene expression after chronic in vivo treatment with the peroxisome proliferator-activated receptor-alpha activator fenofibrate","volume":"279","author":"Gervois","year":"2004","journal-title":"J. Biol. Chem."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.bbrc.2004.09.110","article-title":"PPARalpha ligands activate antioxidant enzymes and suppress hepatic fibrosis in rats","volume":"324","author":"Toyama","year":"2004","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.jhep.2014.10.039","article-title":"Molecular mechanism of PPAR\u03b1 action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease","volume":"62","author":"Pawlak","year":"2015","journal-title":"J. Hepatol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/j.neuropharm.2005.02.013","article-title":"Oleoylethanolamide, an endogenous PPAR-alpha agonist, lowers body weight and hyperlipidemia in obese rats","volume":"48","author":"Fu","year":"2005","journal-title":"Neuropharmacology"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"42530","DOI":"10.18632\/oncotarget.6466","article-title":"Oleoylethanolamide, an endogenous PPAR-\u03b1 ligand, attenuates liver fibrosis targeting hepatic stellate cells","volume":"6","author":"Chen","year":"2015","journal-title":"Oncotarget"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"603","DOI":"10.3945\/jn.110.135210","article-title":"PPARalpha expression protects male mice from high fat-induced nonalcoholic fatty liver","volume":"141","author":"Abdelmegeed","year":"2011","journal-title":"J. Nutr."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"29577","DOI":"10.1074\/jbc.273.45.29577","article-title":"Peroxisome proliferator-activated receptor alpha-isoform deficiency leads to progressive dyslipidemia with sexually dimorphic obesity and steatosis","volume":"273","author":"Costet","year":"1998","journal-title":"J. Biol. Chem."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1053\/jhep.2003.50307","article-title":"Central role of PPARalpha-dependent hepatic lipid turnover in dietary steatohepatitis in mice","volume":"38","author":"Ip","year":"2003","journal-title":"Hepatology"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1002\/hep.26461","article-title":"Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha\/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis","volume":"58","author":"Staels","year":"2013","journal-title":"Hepatology"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.jhep.2015.02.019","article-title":"PPAR\u03b1 gene expression correlates with severity and histological treatment response in patients with non-alcoholic steatohepatitis","volume":"63","author":"Francque","year":"2015","journal-title":"J. Hepatol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1210\/endo.137.1.8536636","article-title":"Differential expression of peroxisome proliferator-activated receptors (PPARs): Tissue distribution of PPAR-alpha, -beta, and -gamma in the adult rat","volume":"137","author":"Braissant","year":"1996","journal-title":"Endocrinology"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"7355","DOI":"10.1073\/pnas.91.15.7355","article-title":"Differential expression and activation of a family of murine peroxisome proliferator-activated receptors","volume":"91","author":"Kliewer","year":"1994","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.2337\/diab.46.8.1319","article-title":"Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-alpha in humans: No alteration in adipose tissue of obese and NIDDM patients","volume":"46","author":"Auboeuf","year":"1997","journal-title":"Diabetes"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/j.1749-6632.1996.tb18620.x","article-title":"Peroxisome proliferator-activated receptors: Structures and function","volume":"804","author":"Tugwood","year":"1996","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"8071","DOI":"10.1074\/jbc.272.12.8071","article-title":"Identification, characterization, and tissue distribution of human peroxisome proliferator-activated receptor (PPAR) isoforms PPARgamma2 versus PPARgamma1 and activation with retinoid X receptor agonists and antagonists","volume":"272","author":"Mukherjee","year":"1997","journal-title":"J. Biol. Chem."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.bbrc.2008.04.086","article-title":"Quantitative expression patterns of peroxisome proliferator-activated receptor-beta\/delta (PPARbeta\/delta) protein in mice","volume":"371","author":"Girroir","year":"2008","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/2045-3701-2-34","article-title":"GW501516-activated PPAR\u03b2\/\u03b4 promotes liver fibrosis via p38-JNK MAPK-induced hepatic stellate cell proliferation","volume":"2","author":"Kostadinova","year":"2012","journal-title":"Cell Biosci."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"3444","DOI":"10.1073\/pnas.0511253103","article-title":"PPARdelta regulates glucose metabolism and insulin sensitivity","volume":"103","author":"Lee","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1152\/physiolgenomics.00127.2009","article-title":"Transcriptional profiling reveals divergent roles of PPARalpha and PPARbeta\/delta in regulation of gene expression in mouse liver","volume":"41","author":"Sanderson","year":"2010","journal-title":"Physiol. Genom."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1074\/jbc.M110.138115","article-title":"Role of peroxisome proliferator-activated receptor {delta}\/{beta} in hepatic metabolic regulation","volume":"286","author":"Liu","year":"2011","journal-title":"J. Biol. Chem."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1101\/gad.8.10.1224","article-title":"mPPAR gamma 2: Tissue-specific regulator of an adipocyte enhancer","volume":"8","author":"Tontonoz","year":"1994","journal-title":"Genes Dev."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"18779","DOI":"10.1074\/jbc.272.30.18779","article-title":"The organization, promoter analysis, and expression of the human PPARgamma gene","volume":"272","author":"Fajas","year":"1997","journal-title":"J. Biol. Chem."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0006-2952(01)00817-6","article-title":"Toxicological consequences of altered peroxisome proliferator-activated receptor gamma (PPARgamma) expression in the liver: Insights from models of obesity and type 2 diabetes","volume":"63","author":"Boelsterli","year":"2002","journal-title":"Biochem. Pharmacol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1023\/A:1011927113563","article-title":"Hepatic over-expression of peroxisome proliferator activated receptor gamma2 in the ob\/ob mouse model of non-insulin dependent diabetes mellitus","volume":"224","author":"Rahimian","year":"2001","journal-title":"Mol. Cell. Biochem."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"4021","DOI":"10.1210\/endo.141.11.7771","article-title":"Up-regulation of peroxisome proliferator-activated receptors (PPAR-alpha) and PPAR-gamma messenger ribonucleic acid expression in the liver in murine obesity: Troglitazone induces expression of PPAR-gamma-responsive adipose tissue-specific genes in the liver of obese diabetic mice","volume":"141","author":"Memon","year":"2000","journal-title":"Endocrinology"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1096\/fj.10-173716","article-title":"Role for PPAR\u03b3 in obesity-induced hepatic steatosis as determined by hepatocyte- and macrophage-specific conditional knockouts","volume":"25","author":"Titos","year":"2011","journal-title":"FASEB J."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"E1195","DOI":"10.1152\/ajpendo.00513.2004","article-title":"PPARgamma2 regulates lipogenesis and lipid accumulation in steatotic hepatocytes","volume":"288","author":"Schadinger","year":"2005","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.2337\/db07-0156","article-title":"Genes involved in fatty acid partitioning and binding, lipolysis, monocyte\/macrophage recruitment, and inflammation are overexpressed in the human fatty liver of insulin-resistant subjects","volume":"56","author":"Westerbacka","year":"2007","journal-title":"Diabetes"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1210\/jc.2010-2129","article-title":"Up-regulation of PPAR-gamma mRNA expression in the liver of obese patients: An additional reinforcing lipogenic mechanism to SREBP-1c induction","volume":"96","author":"Pettinelli","year":"2011","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"34268","DOI":"10.1074\/jbc.M300043200","article-title":"Liver peroxisome proliferator-activated receptor gamma contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass","volume":"278","author":"Gavrilova","year":"2003","journal-title":"J. Biol. Chem."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1172\/JCI200317223","article-title":"Liver-specific disruption of PPARgamma in leptin-deficient mice improves fatty liver but aggravates diabetic phenotypes","volume":"111","author":"Matsusue","year":"2003","journal-title":"J. Clin. Investig."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1016\/j.febslet.2014.05.012","article-title":"Hepatic PPAR\u03b3 and LXR\u03b1 independently regulate lipid accumulation in the livers of genetically obese mice","volume":"588","author":"Matsusue","year":"2014","journal-title":"FEBS Lett."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"37603","DOI":"10.1074\/jbc.M604709200","article-title":"Aberrant hepatic expression of PPARgamma2 stimulates hepatic lipogenesis in a mouse model of obesity, insulin resistance, dyslipidemia, and hepatic steatosis","volume":"281","author":"Zhang","year":"2006","journal-title":"J. Biol. Chem."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1530\/JOE-16-0447","article-title":"Hepatocyte-specific, PPAR\u03b3-regulated mechanisms to promote steatosis in adult mice","volume":"232","author":"Majumdar","year":"2017","journal-title":"J. Endocrinol."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1038\/ncomms1667","article-title":"PPAR\u03b3 contributes to PKM2 and HK2 expression in fatty liver","volume":"3","author":"Panasyuk","year":"2012","journal-title":"Nat. Commun."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1111\/apt.13620","article-title":"Review article: Emerging anti-fibrotic therapies in the treatment of non-alcoholic steatohepatitis","volume":"43","author":"Noureddin","year":"2016","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1055\/s-2006-927395","article-title":"Inflammation, damage repair and liver fibrosis--role of cytokines and different cell types","volume":"45","author":"Saile","year":"2007","journal-title":"Z. Gastroenterol."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"G357","DOI":"10.1152\/ajpgi.00456.2007","article-title":"Endocannabinoids and liver disease. II. Endocannabinoids in the pathogenesis and treatment of liver fibrosis","volume":"294","author":"Siegmund","year":"2008","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/35071088","article-title":"Leptin-regulated endocannabinoids are involved in maintaining food intake","volume":"410","author":"Goparaju","year":"2001","journal-title":"Nature"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.tips.2008.10.001","article-title":"Should peripheral CB(1) cannabinoid receptors be selectively targeted for therapeutic gain?","volume":"30","author":"Kunos","year":"2009","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.cmet.2007.12.007","article-title":"Paracrine activation of hepatic CB1 receptors by stellate cell-derived endocannabinoids mediates alcoholic fatty liver","volume":"7","author":"Jeong","year":"2008","journal-title":"Cell Metab."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1111\/j.1476-5381.2009.00183.x","article-title":"Peripheral endocannabinoid dysregulation in obesity: Relation to intestinal motility and energy processing induced by food deprivation and re-feeding","volume":"158","author":"Izzo","year":"2009","journal-title":"Br. J. Pharmacol."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1111\/j.1478-3231.2005.01180.x","article-title":"Endocannabinoids and liver disease--review","volume":"25","author":"Gabbay","year":"2005","journal-title":"Liver Int."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1002\/oby.21687","article-title":"Serum levels of endocannabinoids are independently associated with nonalcoholic fatty liver disease","volume":"25","author":"Azar","year":"2017","journal-title":"Obesity"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1111\/j.1478-3231.2009.02137.x","article-title":"Circulating and hepatic endocannabinoids and endocannabinoid-related molecules in patients with cirrhosis","volume":"30","author":"Caraceni","year":"2010","journal-title":"Liver Int."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1055\/s-2001-17550","article-title":"History, heterogeneity, developmental biology, and functions of quiescent hepatic stellate cells","volume":"21","author":"Geerts","year":"2001","journal-title":"Semin. Liver Dis."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1582-4934.2006.tb00292.x","article-title":"Modern pathogenetic concepts of liver fibrosis suggest stellate cells and TGF-beta as major players and therapeutic targets","volume":"10","author":"Gressner","year":"2006","journal-title":"J. Cell. Mol. Med."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1002\/hep.20667","article-title":"Anandamide induces necrosis in primary hepatic stellate cells","volume":"41","author":"Siegmund","year":"2005","journal-title":"Hepatology"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1002\/hep.24077","article-title":"Endocannabinoids in liver disease","volume":"53","author":"Tam","year":"2011","journal-title":"Hepatology"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"2798","DOI":"10.1096\/fj.06-7717com","article-title":"The endocannabinoid 2-arachidonoyl glycerol induces death of hepatic stellate cells via mitochondrial reactive oxygen species","volume":"21","author":"Siegmund","year":"2007","journal-title":"FASEB J."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"E298","DOI":"10.1007\/BF02854900","article-title":"Cannabinoid receptors and endocannabinoids: Evidence for new players","volume":"8","author":"Mackie","year":"2006","journal-title":"AAPS J."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S0009-3084(00)00195-X","article-title":"Cannabinoid receptors and the regulation of immune response","volume":"108","author":"Berdyshev","year":"2000","journal-title":"Chem. Phys. Lipids"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0014-2999(00)00437-4","article-title":"Inhibition of nitric oxide production in RAW264.7 macrophages by cannabinoids and palmitoylethanolamide","volume":"401","author":"Ross","year":"2000","journal-title":"Eur. J. Pharmacol."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1074\/jbc.275.1.605","article-title":"Evidence that 2-arachidonoylglycerol but not N-palmitoylethanolamine or anandamide is the physiological ligand for the cannabinoid CB2 receptor. Comparison of the agonistic activities of various cannabinoid receptor ligands in HL-60 cells","volume":"275","author":"Sugiura","year":"2000","journal-title":"J. Biol. Chem."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"663","DOI":"10.2174\/0929867023370707","article-title":"The palmitoylethanolamide family: A new class of anti-inflammatory agents?","volume":"9","author":"Lambert","year":"2002","journal-title":"Curr. Med. Chem."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"G873","DOI":"10.1152\/ajpgi.00241.2011","article-title":"The endocannabinoid N-arachidonoyl dopamine (NADA) selectively induces oxidative stress-mediated cell death in hepatic stellate cells but not in hepatocytes","volume":"302","author":"Wojtalla","year":"2012","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1002\/hep.20733","article-title":"Daily cannabis smoking as a risk factor for progression of fibrosis in chronic hepatitis C","volume":"42","author":"Nguyen","year":"2005","journal-title":"Hepatology"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/89953","article-title":"Endocannabinoids acting at vascular CB1 receptors mediate the vasodilated state in advanced liver cirrhosis","volume":"7","author":"Wagner","year":"2001","journal-title":"Nat. Med."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1111\/liv.12263","article-title":"The endocannabinoid system in advanced liver cirrhosis: Pathophysiological implication and future perspectives","volume":"33","author":"Baldassarre","year":"2013","journal-title":"Liver Int."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1111\/j.1478-3231.2011.02496.x","article-title":"Role of cannabinoid receptors in alcoholic hepatic injury: Steatosis and fibrogenesis are increased in CB2 receptor-deficient mice and decreased in CB1 receptor knockouts","volume":"31","author":"Trebicka","year":"2011","journal-title":"Liver Int."},{"key":"ref_173","first-page":"58","article-title":"Endocannabinoids as novel mediators of liver diseases","volume":"29","author":"Mallat","year":"2006","journal-title":"J. Endocrinol. Investig."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1042\/CS20060260","article-title":"Effect of chronic CB1 cannabinoid receptor antagonism on livers of rats with biliary cirrhosis","volume":"112","author":"Yang","year":"2007","journal-title":"Clin. Sci."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"993","DOI":"10.2353\/ajpath.2008.070720","article-title":"Prevention of hepatic fibrosis in a murine model of metabolic syndrome with nonalcoholic steatohepatitis","volume":"173","author":"DeLeve","year":"2008","journal-title":"Am. J. Pathol."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1053\/j.gastro.2009.01.004","article-title":"Cannabinoid type 1 receptor antagonism delays ascites formation in rats with cirrhosis","volume":"137","author":"Domenicali","year":"2009","journal-title":"Gastroenterology"},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1038\/labinvest.2011.191","article-title":"Reversal of liver fibrosis by the antagonism of endocannabinoid CB1 receptor in a rat model of CCl(4)-induced advanced cirrhosis","volume":"92","author":"Giannone","year":"2012","journal-title":"Lab. Investig."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"6323","DOI":"10.1073\/pnas.1017689108","article-title":"Hyperactivation of anandamide synthesis and regulation of cell-cycle progression via cannabinoid type 1 (CB1) receptors in the regenerating liver","volume":"108","author":"Mukhopadhyay","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1002\/hep.23779","article-title":"Beneficial paracrine effects of cannabinoid receptor 2 on liver injury and regeneration","volume":"52","author":"Belot","year":"2010","journal-title":"Hepatology"},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1124\/jpet.107.131896","article-title":"Regression of fibrosis after chronic stimulation of cannabinoid CB2 receptor in cirrhotic rats","volume":"324","author":"Ros","year":"2008","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1124\/jpet.111.188078","article-title":"Prevention of fibrosis progression in CCl4-treated rats: Role of the hepatic endocannabinoid and apelin systems","volume":"340","author":"Reichenbach","year":"2012","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1002\/hep.26598","article-title":"Cannabinoid receptor 2 counteracts interleukin-17-induced immune and fibrogenic responses in mouse liver","volume":"59","author":"Guillot","year":"2014","journal-title":"Hepatology"},{"key":"ref_183","doi-asserted-by":"crossref","unstructured":"Rossi, F., Bellini, G., Alisi, A., Alterio, A., Maione, S., Perrone, L., Locatelli, F., Miraglia del Giudice, E., and Nobili, V. (2012). Cannabinoid receptor type 2 functional variant influences liver damage in children with non-alcoholic fatty liver disease. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0042259"},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1172\/JCI88881","article-title":"Liver inflammation and fibrosis","volume":"127","author":"Koyama","year":"2017","journal-title":"J. Clin. Investig."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.jhep.2016.04.018","article-title":"Sinusoidal communication in liver fibrosis and regeneration","volume":"65","author":"Marrone","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1016\/S0016-5085(99)70407-5","article-title":"Rat liver myofibroblasts and hepatic stellate cells: Different cell populations of the fibroblast lineage with fibrogenic potential","volume":"117","author":"Knittel","year":"1999","journal-title":"Gastroenterology"},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/j.jhep.2014.05.047","article-title":"Vascular pathobiology in chronic liver disease and cirrhosis - current status and future directions","volume":"61","author":"Iwakiri","year":"2014","journal-title":"J. Hepatol."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1016\/j.jhep.2015.07.004","article-title":"Mechanisms of decompensation and organ failure in cirrhosis: From peripheral arterial vasodilation to systemic inflammation hypothesis","volume":"63","author":"Bernardi","year":"2015","journal-title":"J. Hepatol."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1053\/jhep.2002.31432","article-title":"The paradox of nitric oxide in cirrhosis and portal hypertension: Too much, not enough","volume":"35","author":"Wiest","year":"2002","journal-title":"Hepatology"},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"S121","DOI":"10.1016\/j.jhep.2015.01.003","article-title":"Evolution in the understanding of the pathophysiological basis of portal hypertension: How changes in paradigm are leading to successful new treatments","volume":"62","author":"Bosch","year":"2015","journal-title":"J. Hepatol."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1038\/sj.bjp.0706928","article-title":"Anandamide mediates hyperdynamic circulation in cirrhotic rats via CB(1) and VR(1) receptors","volume":"149","author":"Moezi","year":"2006","journal-title":"Br. J. Pharmacol."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1096\/fasebj.12.11.1035","article-title":"Platelet- and macrophage-derived endogenous cannabinoids are involved in endotoxin-induced hypotension","volume":"12","author":"Varga","year":"1998","journal-title":"FASEB J."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"45034","DOI":"10.1074\/jbc.M306062200","article-title":"Lipopolysaccharide induces anandamide synthesis in macrophages via CD14\/MAPK\/phosphoinositide 3-kinase\/NF-kappaB independently of platelet-activating factor","volume":"278","author":"Liu","year":"2003","journal-title":"J. Biol. Chem."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1136\/gut.2004.051599","article-title":"Increased anandamide induced relaxation in mesenteric arteries of cirrhotic rats: Role of cannabinoid and vanilloid receptors","volume":"54","author":"Domenicali","year":"2005","journal-title":"Gut"},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.jcma.2015.05.005","article-title":"Alteration of intrahepatic microcirculation in cirrhotic livers","volume":"78","author":"Yang","year":"2015","journal-title":"J. Chin. Med Assoc."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1124\/jpet.102.041095","article-title":"Potentiation of anandamide effects in mesenteric beds isolated from endotoxemic rats","volume":"304","author":"Orliac","year":"2003","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1002\/hep.29104","article-title":"Left ventricular systolic function is associated with sympathetic nervous activity and markers of inflammation in cirrhosis","volume":"65","author":"Yotti","year":"2017","journal-title":"Hepatology"},{"key":"ref_198","first-page":"H2085","article-title":"Cannabinoid CB1 receptor of cat cerebral arterial muscle functions to inhibit L-type Ca2+ channel current","volume":"276","author":"Gebremedhin","year":"1999","journal-title":"Am. J. Physiol."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"H1689","DOI":"10.1152\/ajpheart.00538.2007","article-title":"Endocannabinoids acting at CB1 receptors mediate the cardiac contractile dysfunction in vivo in cirrhotic rats","volume":"293","author":"Mukhopadhyay","year":"2007","journal-title":"Am. J. Physiol. Heart Circ. Physiol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/20\/10\/2516\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T12:54:08Z","timestamp":1760187248000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/20\/10\/2516"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,22]]},"references-count":199,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2019,5]]}},"alternative-id":["ijms20102516"],"URL":"https:\/\/doi.org\/10.3390\/ijms20102516","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,22]]}}}